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Abstract
Background: Patellar tendinopathy is a major problem for many athletes, especially those involved in jumping
activities. Despite its frequency and negative impact on athletic careers, no evidence-based guidelines for
management of this overuse injury exist. Since functional outcomes of conservative and surgical treatments remain
suboptimal, new diagnostic and therapeutic strategies have to be developed and evaluated.
Extracorporeal shockwave therapy (ESWT) appears to be a promising treatment in patients with chronic patellar
tendinopathy. ESWT is most often applied after the known conservative treatments have failed. However, its effec-
tiveness as primary therapy has not been studied in athletes who keep playing sports despite having patellar ten-
don pain.
The aim of this study is to determine the effectiveness of ESWT in athletes with patellar tendinopathy who are still
in training and competition.
Methods/design: The TOPGAME-study (Tendinopathy of Patella Groningen Amsterdam Maastricht ESWT) is a
multicentre two-armed randomised controlled trial with blinded participants and outcome assessors, in which the
effectiveness of patient-guided focussed ESWT treatment (compared to placebo ESWT) on pain reduction and
recovery of function in athletes with patellar tendinopathy will be investigated. Participants are volleyball, handball
and basketball players with symptoms of patellar tendinopathy for a minimum of 3 to a maximum duration of 12
months who are still able to train and compete. The intervention group receives three patient-guided focussed
medium-energy density ESWT treatments without local anaesthesia at a weekly interval in the first half of the
competition. The control group receives placebo treatment. The follow-up measurements take place 1, 12 and 22
weeks after the final ESWT or placebo treatment, when athletes are still in competition. Primary outcome measure
is the VISA-P (Victorian Institute of Sport Assessment - patella) score. Data with regard to pain during function tests
(jump tests and single-leg decline squat) and ultrasound characteristics are also collected. During the follow-up
period participants also register pain, symptoms, sports participation, side effects of treatment and additional
medical consumption in an internet-based diary.
Discussion: The TOPGAME-study is the first RCT to study the effectiveness of patient-guided ESWT in athletes with
patellar tendinopathy who are still in training and competition.
Trial registration: Trial registration number NTR1408.
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Patellar tendinopathy (’jumper’s knee’) is a clinical con-
dition of gradually progressive activity-related pain at
the insertion of the patellar tendon at the apex patellae
[1]. Prolonged repetitive stress of the knee-extensor
apparatus can lead to this common overuse tendinopa-
thy in athletes from different sports [2]. The overall pre-
valence of patellar tendinopathy among elite and non-
elite athletes is high and varies between 3 and 45% [3,4].
In sports characterised by high demands on speed and
power for the leg extensors, such as volleyball and bas-
ketball a prevalence of respectively 44.6% and 31.9% has
been reported [4]. In sports medicine centres patellar
tendinopathy is one of the leading causes for athletes to
consult physicians or physical therapists. Patellar
tendinopathy often contributes to the decision to quit
an athletic career and also causes mild but long-lasting
symptoms after an athletic career [5]. The high preva-
lence, impact on sports performance, and chronic nature
of the condition all mean that in some jumping sports,
patellar tendinopathy may cause at least as much
impairment in athletic performance as acute knee inju-
ries [4].
There is no consensus on what is the most appropri-
ate treatment for patellar tendinopathy [6,7]. Several
conservative treatment modalities (e.g. physical therapy,
anti-inflammatory medication, rest, exercise) and differ-
ent surgical procedures for treatment of patellar tendi-
nopathy have been described [8,9,6,7]. Overall, they have
n o tb e e np r o v e nt ob eh i g h l ys u c c e s s f u li nr e l i e v i n g
Figure 1 TOPGAME Trial profile. The Trial profile of the TOPGAME study.
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Page 2 of 6symptoms to such a degree that athletes can continue to
participate in their sport at their full potential [8]. New
treatment modalities for patellar tendinopathy have
recently been introduced, based on the finding that the
pathology underlying chronic (patellar) tendinopathies is
not inflammatory tendinitis but a degenerative tendino-
sis due to a failed healing response [10].
In the last few years, extracorporeal shockwave ther-
apy (ESWT) has also been used for the treatment of
patellar tendinopathy. It seems to be a safe and promis-
ing treatment for patellar tendinopathy [11]. In most of
the research on ESWT treatment for patellar tendinopa-
thy to date, patients have been recruited in a referral-
based specialist care setting. Moreover, ESWT is often
only applied when other treatments have already failed.
This means that most patients included in these studies
have serious, chronic problems, generally to the extent
that they had to stop sports participation entirely, or at
least reduce their level of sports participation signifi-
cantly. One can presume that patients in this stage have
a decreased healing tendency and are possibly less
responsive (more resistant) to all treatment modalities.
To our knowledge, the effectiveness of ESWT has not
been systematically investigated in athletes who have
early symptomatic patellar tendinopathy and are still
actively competing.
T h ea i mo ft h eT O P G A M Es t u d yi st od e t e r m i n et h e
effectiveness of ESWT on pain, symptoms and function,
in athletes with patellar tendinopathy at an early stage
of the disease who are still in training and competition.
Methods/Design
Design
The TOPGAME study (Tendinopathy Of Patella Gro-
ningen Amsterdam Maastricht ESWT) is a multicentre
randomised controlled trial with blinded participants
and outcome assessors, using a two-group repeated
measures design with a treatment period of 2 weeks and
a 22 week follow-up. Participants are randomized into
an intervention ESWT group or a placebo control
group. Recruitment of participants for the TOPGAME
trial takes place in May-November 2008 and data collec-
tion starts in September 2008 (first half of the competi-
tion season). The ESWT and placebo treatments start in
October 2008. After three ESWT or placebo treatments,
the follow-up measurements take place at 1, 12 and 22
weeks after the final treatment, when athletes are still in
competition. The trial profile is shown in Figure 1.
The study design, procedures and informed consent
procedure were approved by the Medical Ethics Com-
mittee (Number 2008/052) of the University Medical
Center Groningen (UMCG), the Netherlands. All parti-
cipants have to provide written informed consent.
Study population
Recruitment of the participants is facilitated by the
Dutch Basketball Association (Nederlandse Basketbal-
bond, NBB), Dutch Handball Association (Nederlands
Handbalverbond, NHV) and the Dutch Volleyball Asso-
ciation (Nederlandse Volleybalbond, NEVOBO).
Through both an advertisement on their website and an
e-mail sent to all their athletes (aged 18-35) and the
coaches of the club teams, attention is drawn to the
TOPGAME-study. Recruitment is further assisted by
advertisements in local, regional and national newspa-
pers and by advertising at tournaments and games.
All athletes are invited to fill out a questionnaire on
sports participation and knee problems (including a pain
map) on a specially designed website http://www.topga-
mestudie.nl. They are also asked for their willingness to
participate in the study. After this questionnaire-based
screening, participants with a high likelihood of having
patellar tendinopathy are contacted by mail or phone
and sent written information about the study. If they
still want to participate, they receive an invitation for a
consultation by one of the two sports medicine physi-
cians of the study (FH, JZ) at a sports medicine practice
in their neighbourhood. The sports medicine physicians
examine all the participants and clinically establish the
diagnosis of patellar tendinopathy using the criteria
described below. Eligible participants are included in the
study after informed consent. Thereafter, baseline mea-
surements are carried out and athletes will be rando-
mised to either the intervention (ESWT) group or the
control (placebo) group.
Inclusion and exclusion criteria
Male and female basketball, handball and volleyball
players with the following criteria are eligible for
inclusion:
1. History of knee pain in the patellar tendon or its
patellar or tibial insertion (pointed out in an anatomical
drawing of the knee) in connection with training and
competition.
2. Symptoms for over three months in the actual sea-
son or in the second half of the previous season (Janu-
ary-May 2008) (to exclude acute inflammatory tendon
problems and de novo partial ruptures).
3. Age 18-35 years (to reduce chances of osteochon-
drotic diseases like Sinding-Larsen-Johanson, Osgood-
Schlatter and osteoarthrosis).
4. Palpation tenderness at the corresponding painful
area.
5. VISA-P score < 80. The VISA-P (Victorian Institute
of Sport Assessment - patella) score is a short question-
naire measuring the severity of patellar tendinopathy by
assessing pain, function and ability to play sports [12,13].
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acute patellar tendon injuries, have chronic joint dis-
eases or have signs or symptoms of other (co-)existing
knee pathologies. Athletes who use drugs with a puta-
tive effect on patellar tendinopathy in the last year on
daily basis (e.g. non-steroid anti-inflammatory drugs,
fluorquinolones) or use anticoagulants, and athletes who
had knee surgery or injection therapy with corticoster-
oids in the last preceding three months are also
excluded. Athletes with contraindications for ESWT
treatment (pregnancy, malignancy, coagulopathy) are
also excluded from the study.
Randomization
Volleyball, handball and basketball players with patellar
tendinopathy are allocated randomly and blinded to an
intervention group (patient-guided ESWT) or a control
group (placebo treatment) by an independent statistician
(EV) who is blinded for any baseline characteristics of the
participants. Randomisation is performed before the first
treatment by means of a computer-generated randomisa-
tion list (SPSS 16, Chicago, USA). The randomisation
procedure takes place at team level, resulting in players
from the same teams being allocated to the same group.
While the different treatment methods within the study
groups potentially have various immediately noticeable
effects on the subjects (e.g. level of pain), this method of
randomisation is chosen to keep the treatment group
blinded to the subjects, and to avoid spill-over of the
intervention. The independent physical therapists who
administer the ESWT or placebo treatment are informed
by the statistician about the group allocation. Group allo-
cation is concealed from the athletes and the outcome
assessor at all times during the trial.
Intervention
ESWT treatment and placebo treatments will be given
by five independent physical therapists at four different
locations across the Netherlands.
ESWT treatment
The physical therapist will explain the treatment proce-
dure to the athlete and will palpate the patellar tendon to
find the most painful spot. ESWT is applied according to
the guidelines of the International Society for Musculos-
keletal Shockwave Therapy (ISMST) using a piezo-elec-
tric ESWT device (Piezowave, Wolf GmbH, Knittlingen,
Germany). This will be administered in three sessions at
one-week intervals using 2000 impulses at a frequency of
4 Hz. The energy flux density will be titrated according
to individual pain tolerance up to a possible maximum of
0.58 mJ/mm2 (level 20). Treatment will start at level 5
(0.1 mJ/mm2). The athlete will be told that treatment
can be painful but that there is inter-individual variability
in pain perception. After every 100 impulses the physical
therapist will ask the athlete, if he/she can tolerate the
treatment. If he/she can, the physical therapist will
increase the energy flux density by one level, up to the
aforementioned maximum level. A transmission gel will
be applied between the applicator and the focussing pad
as well as between the focussing pad and the skin of the
patient to optimise shockwave transmission to the
patient. No local anaesthesia will be used, since Rompe
and colleagues demonstrated that repetitive application
of shockwaves is more effective without than with local
anaesthesia [14]. The athlete will be in supine position
with an extended knee and shockwaves will be focused
on the painful zone in the tendon or insertion. The infer-
ior pole of the patella will be tilted to focus on the dorsal
insertion of the patellar tendon as well. The aforemen-
tioned treatment protocol was chosen based on our pre-
vious experience with ESWT application in patients with
patellar tendinopathy (submitted). All patients in the
pilot study tolerated this procedure well without adverse
complications.
Placebo treatment
The treatment procedure for the athletes in the control
group is nearly the same. Placebo treatment will be
administered using the same device. The transmission
gel will be applied between the focussing pad and skin
of the patient, but not between applicator and focussing
pad. This is invisible for the athletes, since it is inside of
the device. In this way shockwaves are not or hardly
conducted. Measurements of energy density provided by
the manufacturer for this placebo set-up revealed negli-
gible or only very low energy densities of less than 0,03
mJ/mm2 (Wolf GmbH, Knittlingen, Germany). The ath-
lete will also be told that treatment can be painful but
that there is inter-individual variability in pain percep-
tion. By pressing the applicator with focussing pad to
the painful spot, athletes will also experience some pain.
The physical therapist will also ask after every 100
impulses if the athlete can tolerate the ESWT treatment,
b u te n e r g yf l u xd e n s i t yw i l ln o ti n c r e a s ed u r i n gt h e
treatment. Athletes in the placebo group will also hear
the repetitive impulses generated by the ESWT-device,
yet will be unaware of the dosage administered.
Concurrent sports participation and medical treatment
No restrictions will be given for both groups with regard
to sport participation or concurrent medical treatment.
If the athlete will experience an increase in pain in the
first 48 hours after treatment he/she will be advised to
take paracetamol up to a maximum dose of 3 dd 1000
mg for pain relief.
Measurements
Baseline
After informed consent the following baseline measure-
ments will be carried out:
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The baseline questionnaire consists of three parts. Part 1
covers demographic variables such as name, address,
age, gender, and e-mail address. Sports participation will
be assessed in part 2 by using questions concerning type
and level of sport and mean hours of sports participa-
tion and sport history. Information about medical his-
tory, knee injuries and previous medical treatment will
be collected in the third part of the questionnaire.
VISA-P questionnaire
The primary outcome of the TOPGAME study is the
self-reported VISA-P score [12]. The VISA-P score is a
simple, reliable instrument for measuring the severity of
patellar tendinopathy and is sensitive to small changes
in symptoms. It was specifically designed for patellar
tendinopathy, rating pain, symptoms, simple test of
function and the ability to play sports. Six of the eight
questions are scored on a scale from 0 to 10 points,
with 10 representing optimal health. The maximum
VISA score for an asymptomatic athlete is 100 points.
Validity and reliability of the Dutch translation of the
VISA-P score have been demonstrated recently [13].
VAS pain
Secondary outcome parameters are ratings of pain on a
Visual Analogue Scale (VAS) during activities of daily
living (ADL) and sports, and during functional tests like
maximal jumping tests, triple hop test and the single leg
decline squat (SLDS); the latter test, in which the athlete
performs a single-leg squat to 60° of knee flexion on a
25° decline board ten times, was designed to preferen-
tially load the patellar tendon [15,16].
Ultrasound
Greyscale ultrasound and Power/Colour Doppler char-
acteristics of the patellar tendon (hypo-echogenity, dia-
meter, calcifications, and degree of neovascularisation)
will be collected by an experienced radiologist.
Follow-up
Follow-up measurements for VISA-P and the VAS pain
assessments will be carried out at 1, 12 and 22 weeks
after the final treatment, when athletes are still in
competition. Side effects and adverse reactions/events
and the rate of overall treatment satisfaction will also
be recorded. At 22 weeks after final treatment, ultra-
sound characteristics will be collected by the same
experienced radiologist who is blinded to the athletes’
group allocation. Further both groups of athletes will
be recording their athletic activities and concurrent
medical treatment on a weekly basis, using a web-
based diary.
Sample size
Sample size is calculated based on the VISA-P score.
From previous investigations a baseline score of 64
points is expected in symptomatic athletes (95 points in
athletes without patellar tendinopathy), with an SD of
19 points (2). (To our knowledge no data are available
that describe the SD of the difference between the base-
line and 6 month VISA-score.)
A 15-point difference in the VISA score between the
treatment and placebo is considered to be clinically rele-
vant. To detect a difference of 15 points on the VISA
scale with an SD of 19, a power of 90% and an alpha of
5%, 34 subjects per group are needed.
The proposed treatment protocol without local anaes-
thesia and with patient-guided dosage (for pain toler-
ance) is chosen based on our previous experience with
ESWT application in patients with patellar tendinopathy
(J. Zwerver, submitted). All patients tolerated this proce-
dure well without adverse complications; therefore we
do not expect a higher-than-normal drop-out rate of
athletes due to pain during the treatment. Assuming a
drop-out rate of about 20% this would mean that a total
of 86 subjects are required at baseline (43 in each
group).
Statistical analyses
Descriptive statistics (means and standard deviations,
numbers and percentages) will be used to describe the
characteristics of the intervention and control group
and the outcome variables at the three measurement
points. To evaluate potential group differences at the
start of the study, baseline values will be analysed for
differences between intervention group and control
group. The effect of the ESWT treatment will be
assessed using multilevel analysis. The multilevel analy-
sis will be used to determine whether there is a differ-
ence on the primary and secondary outcome variables
between the two groups over time. This statistical tech-
nique takes into account the dependency of observations
of different subjects. Analyses will be adjusted for gen-
der, age, type of sport, and baseline values of any other
post hoc confounders. Analyses will be performed fol-
lowing the ‘intention to treat’ principle. Differences will
be considered statistically significant at p < 0.05. All
analyses will be done using SPSS version 16 (SPSS, Chi-
cago, USA).
Discussion
Despite its frequency and impact on athletic careers, and
decades of research notwithstanding, management of
patellar tendinopathy remains frustrating and unpredict-
able for both athletes and clinicians. ESWT appears to
be a promising treatment method in patients with
chronic patellar tendinopathy [11]. Up to now, only stu-
dies have been published in which ESWT has been used
for the treatment of recalcitrant patellar tendinopathy in
athletes who had several conservative treatments before
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ment for ESWT [11]. However, the effectiveness of
ESWT has not been studied in the large group of ath-
letes who continue sports participation with an early or
mild symptomatic patellar tendinopathy. The TOP-
GAME study is the first RCT to study the effectiveness
of patient-guided piezo-electrically generated ESWT in
athletes with patellar tendinopathy who are still in train-
ing and competition. To our knowledge, it is also the
first study that takes into account the training and com-
petition load of the athletes using a web-based log.
This study will contribute to a better understanding of
the effectiveness of ESWT as treatment for athletes with
patellar tendinopathy who are still able to train and
compete. By treating them at an early phase, we can get
relevant information on whether it is possible to reverse
or stop the progression of patellar tendinopathy, thereby
preventing chronic impairment of athletic performance,
work and daily activities.
Conclusions
T h eT O P G A M Es t u d yi st h ef i r s tR C Tt oe v a l u a t et h e
effectiveness of patient-guided ESWT in athletes with
early-phase symptomatic patellar tendinopathy who are
still in training and competition.
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